KawanishiH.The pathogenesis and therapeutic option of encapsulating peritoneal sclerosis.Int J Artif Organs2005; 28: 150–5.
2.
WilliamsJ.D., CraigK.J., von RuhlandC., TopleyN., WilliamsG.T.The natural course of peritoneal membrane biology during peritoneal dialysis.Kidney Int Suppl2003; 88: S43–9.
IoH., HamadaC., RoY., ItoY., HiraharaI., TominoY.Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models.Kidney Int2004; 65: 1927–36.
5.
LiuL., ShiC.X., GhayurA., ZhangC., SuJ.Y., HoffC.M.Prolonged peritoneal gene expression using a helperdependent adenovirus.Perit Dial Int2009; 29: 508–16.
6.
MargettsP.J., BonniaudP.Basic mechanisms and clinical implications of peritoneal fibrosis.Perit Dial Int2003; 23: 530–41.
7.
MiyazakiM., YuzawaY.The role of peritoneal fibrosis in encapsulating peritoneal sclerosis.Perit Dial Int2005; 25(Suppl 4): S48–56.
8.
SugaH., TeraokaS., OtaK., KomemushiS., FurutaniS., YamauchiS.Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats.Exp Toxicol Pathol1995; 47: 287–91.
9.
SummersA.M.Encapsulating peritoneal sclerosis—have we found the perpetrator?Perit Dial Int2009; 29: 499–501.
10.
SampimonD.E., KorteM.R., Lopes BarretoD., VlijmA., de WaartR., StruijkD.G.Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study.Perit Dial Int2010; 30: 163–9.
11.
TopleyN., MichaelD., BowenT.CA125: holy grail or a poisoned chalice.Nephron Clin Pract2005; 100: c52–4.
12.
GillerotG., GoffinE., MichelC., EvenepoelP., van BiesenW., TintillierM.Genetic and clinical factors influence the baseline permeability of the peritoneal membrane.Kidney Int2005; 67: 2477–87.
